



LifeSciences
British Columbia



Medical Devices & Diagnostics

Leveraging a track record of developing disruptive medical device and diagnostic technologies to build British Columbia's next generation of commercial success stories.


Contents

A History of Successful Innovation:	2
Now Hitting the Market	5
Strong Support & Co-Development Resources:	6
The Next Wave of Medical Device & Diagnostic Innovators	8
A Fertile Landscape.....	9
Further Fueling Medical Device & Diagnostic Commercialization in BC.....	11
Leveraging Our Industry Leaders:	12
Compelling Incentives	13
A Dedicated Industry Association	14
In Summary.....	15
Contact us	16
Defining the Terms.....	17

Medical Devices & Diagnostics

Leveraging a track record of developing disruptive medical device and diagnostic technologies to build British Columbia's next generation of commercial success stories.

The Medical Device & Diagnostic sector in British Columbia has long been a diverse community of small to medium innovators challenging the methodology, efficiency and efficacy of conventional medical instruments and procedures.



There are approximately 90 Medical Device & Diagnostic companies in British Columbia ranging from early-stage prototype developers to mature companies with sales to contract technology engineering firms. At any stage of development, these companies are innovating at the edge of current technology and pioneering entirely new platforms for detection and treatment of medical conditions. Whether it be precisely activating a drug with light, applying a pharmaceutical coating to a coronary stent, detecting urinary obstruction without invasive catheters or using a gene profile to save the lives of sepsis patients, British Columbia is developing not only better devices, but leading the shift towards altogether new device and diagnostic paradigms.

A History of Successful Innovation


Two of the world's first profitable biotechnology companies, QLT Inc. and Angiotech Pharmaceuticals, were born and bred here in British Columbia, and became important anchors for the development of BC's biotech and life sciences cluster. Incidentally, the lead products that brought both these companies to success include both a medical device and a pharmaceutical component. These companies and their breakthrough products are as follows:

- **QLT Inc.** (www.qltinc.com): Previously referred to as QLT Phototherapeutics, QLT launched commercial sales of Visudyne with its partner Novartis in the United States in April of 2003 for the treatment of certain types of Age-Related Macular Degeneration (AMD). Almost immediately after launch, the company became profitable with Visudyne recording first quarter commercial sales of USD \$25M. Visudyne is a light activated drug that employs photodynamic therapy to treat ophthalmology and autoimmune disease. QLT has since diversified its business into other product areas and continues to focus its efforts specifically on ocular conditions.
- **Angiotech Pharmaceuticals** (www.angiotech.com): In 2005, Angiotech, with its partner Boston Scientific, launched US sales of its TAXUS Liberte^(TM) bare-metal coronary stent. With first year sales nearing \$2.7 billion US, it was the most successful medical product launch in history. The TAXUS stent is unique compared to other stents as it is coated with the active pharmaceutical Paclitaxel which elutes into the surrounding tissue to prevent further clogging. With the acquisition of American Medical Holdings in 2006, Angiotech diversified its business to develop, manufacture and market a wide array of complimentary products in the areas of plastic and ophthalmic surgery, vascular surgery, interventional radiology and tumor biopsy. Angiotech remains an active leader in, and supporter of, the British Columbia life sciences sector.

Other ongoing, British Columbia, Medical Device & Diagnostic success stories include the following:

- **McKesson Canada** (www.mckesson.ca): McKesson Canada established its Medical Imaging Group in Vancouver in 2002 through its acquisition of acquisition of A.L.I. Technologies – at the time the leading provider of enterprise medical image





management solutions, also known as PACS (Picture Archiving and Communications Systems). The A.L.I product line, now known as Horizon Medical Imaging, expanded McKesson's Horizon Clinicals suite to include medical images. Horizon Clinicals is McKesson's integrated suite of solutions for physicians and other clinicians in multiple care settings. McKesson was established in 1833 and, with annual revenues of more than US\$50 billion, it ranks in the top 50 largest industrial companies in the United States.

- **Ultrasonix Medical** (www.ultrasonix.com): Ultrasonix is a leading developer and manufacturer of high quality diagnostic ultrasound imaging systems, having carved a substantial, successful niche for itself right alongside the huge ultrasound equipment companies such as Siemens & GE. Ultrasonix's CEP system has solidified it as a leader in competitively priced, compact ultrasound systems. Its OpenSONIX ultrasound technology provides superior image quality, ease of use and clinical flexibility to adapt to the needs of a variety of specialties. Founded by electrical engineer Laurent Pellisier, Ultrasonix is privately held and employs some 70 people in Richmond, BC with affiliate dealers in 65 countries. Ultrasonix is one of BC's largest and most successful medical device stories and winner of the SALMED Gold Medal Award in 2010 for showcasing products that boast cutting-edge technological solutions and top quality.
- **Neoteric Technology** (www.neoteric.com): Neoteric was founded in 1997 with the objective of helping hospital laboratories reduce bottlenecks in the management of samples and patient information in. By electronically connecting positive patient identification to everything that is given to or taken from a patient while they are in the hospital, Neoteric has since grown into a world leader in patient safety. Neoteric's goal remains to make healthcare safer for the patient, simpler for the caregiver and less expensive for the organization. In April 2009, Neoteric was acquired by Haemonetics, but continues to operate in Vancouver developing solutions that track and control the collection, administration and movement of products used in direct patient care. Neoteric products are installed in over 200 hospitals in 5 countries. Its BloodTrack application monitors the movement of over 1,000,000 blood units a year while AutoCard digitally archives request forms in over 25% of the laboratories in the UK. Neoteric has won numerous awards including the Microsoft MS-HUG and GC Innovation first place prizes and was LifeSciences British Columbia's 2010 Medical Device Company of the Year.



- **Pyng Medical** (www.pyng.com): Pyng Medical Corporation has been on the leading edge of intraosseous infusion since the launch of its FAST₁ Intraosseous Infusion System in 1997. Pyng's proprietary, award-winning FAST₁ system was created to provide life saving tools to men and women who respond to life threatening situations, whether in hospital, on the street, or in the battlefield. FAST₁ is used extensively by the U.S. Department of Defense, NATO allies, in hospitals and by Emergency Medical Services (EMS) throughout the world. With \$6.5M in sales in 2008, Pyng is now expanding internationally, penetrating new clinical applications, and is poised to diversify with complementary product lines.
- **Response Biomedical** (www.responsebio.com): Response Biomedical, winner of LifeSciences British Columbia's Medical Device Company of the Year Award in 2009, develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP Platform for clinical and environmental applications. RAMP provides high sensitivity and reliable information in mere minutes, is suited to both point of care testing and laboratory use, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP clinical tests are commercially available for the early detection of heart attack, congestive heart failure, influenza and RSV through Response's commercial partners, Roche and 3M Health Care respectively. In the non-clinical market, RAMP Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. Response Biomedical recorded overall sales of approximately \$6M in 2008.
- **Verathon Canada**: In his capacity as a vascular surgeon, Dr. J. Pacey – inventor, researcher and native British Columbian – recognized a clear need for improvement in anesthesia intubations. The outcome of this was a new product development program in Canada to integrate imaging technology with laryngoscopy to provide appropriate access space and reliable visualization to aid in intubation of difficult airways. This pioneering work resulted in the establishment of Saturn Biomedical Systems in 1999 followed by the introduction of the innovative GlideScope Video Laryngoscope in 2001. GlideScope provides a consistently clear view of the airway, enables quick intubation, and offers significant benefits to Anesthesiology, Surgery, and Emergency Medicine practitioners. Saturn and the GlideScope were acquired by Verathon in January 2006.

In addition, through strategic acquisition of BC-born innovations, British Columbia is home to the Canadian offices of several international technology and diagnostic companies including Sorin Group – Mitroflow Division (www.sorin-ushv.com) and LifeScan Canada (www.onetouch.ca).

Now Hitting the Market

Recently, several additional British Columbia Medical Device & Diagnostic companies have entered the commercial phase of their business with products approved for sale in North American and international markets. In each case, these companies have successfully engineered, clinically tested and received market approval for more efficient, effective and safe improvements to existing medical products, procedures and diagnostics. Some of the notable British Columbia companies currently making their foray into the market include the following:

- **Neovasc** (www.neovasc.com): Neovasc Inc. is a specialty vascular device company that develops, manufactures and markets medical technology for the rapidly growing vascular and surgical marketplace. The company's current products include the Neovasc Reducer, a novel product in development to treat refractory angina, as well as a line of advanced biological tissue technologies that are used to enhance surgical outcomes and are key components in a variety of third-party medical products, such as percutaneous heart valves.
- **Kardium** (www.kardium.com): Founded in 2007 by a team largely with experience from CREO Inc. and a track record of excellence in medicine, business, and engineering, Kardium is developing new devices to address cardiovascular diseases. In 2009, Kardium commercially launched its Torq device, a safer, faster and more effective system for sternal closure following open chest surgery. The company has two additional, percutaneous devices in late stage development for treatment of atrial fibrillation and mitral valve regurgitation, designed to drastically reduce the incidence of stroke, heart failure and cardiac arrest in these patients.



- **Progressive Health Innovations** (www.progressivehealth.ca): Progressive Health develops user-friendly and affordable products for the multi-billion dollar rehabilitation, sports medicine and fitness markets. Their first product is AFX (www.afx-online.com), a revolutionary new device that enables users to strengthen the entire foot and ankle complex. Through its innovative design and multiple resistance levels, AFX is a complete strengthening technology that can be used from post-surgical rehab through to improving an elite athlete's performance. AFX counts amongst its initial customers world-renowned sports medicine clinics, research institutes, Olympic athletes, and teams from the National Basketball Association, National Football League and Major League Soccer.

Strong Support & Co-Development Resources

British Columbia is not only proud to be home to many innovative Medical Device & Diagnostic product companies, but also to several highly experienced and skilled technology development and service organizations including:

- **eVasc Medical Systems** (www.evasc.com): eVasc Medical Systems has a strong background in interventional medicine and proven expertise in medical device design, prototyping and production. eVasc focuses its efforts on the development of medical device technologies for the treatment of vascular disease with a mandate to take early-stage intellectual property from concept to pilot production and clinical evaluation.
- **StarFish Medical** (www.starfishmedical.com): For over 10 years, StarFish Medical has been designing, developing and manufacturing world-class medical devices. StarFish specializes in electro-mechanical devices, diagnostic and imaging equipment, with expertise in a broad range of areas, including ophthalmology, handheld devices, dental equipment and radiation therapy.
- **BCIT PART** (www.bcit.ca/appliedresearch/part): The Product and Process Applied Research Team at the British Columbia Institute of Technology has provided applied research services to academic institutions, companies, inventors and entrepreneurs throughout BC and abroad. PART develops, validates and commercializes medical, industrial and consumer products and processes, and performs contract services to research and develop proof of concept prototypes.
- **Dr. Tong Louie Living Lab** (www.sfu.ca/livinglab): Officially opened in November 1997, the Dr. Tong Louie Living Lab conducts research and training activities that aim to improve the relationship between people and their living and working environments. Its goal is to create environments and products that facilitate independent living, sensitive to the needs of older adults and persons with disabilities. The Dr. Tong Louie Living Lab, so named after the founding donor, is a research facility built through the collaborative efforts of Simon Fraser University's Gerontology Research Centre and the British Columbia Institute of Technology's Technology Centre.





BC is home to highly experienced and skilled technology development and services organizations.

- **The Neil Squire Society** (www.neilsquire.ca): The Neil Squire Society is the only not-for-profit organization in Canada that, for the past 25 years, has used technology, knowledge and passion to empower Canadians with physical disabilities. The Society has developed innovative programs and services and some of the world's leading edge assistive technology for people with physical disabilities. More than 20,000 people with disabilities in Canada have benefited from the work of the Society.
- **The GF Strong Rehabilitation Centre** (www.gfstrong.vch.ca): Established in 1949, the GF Strong Rehabilitation Centre is British Columbia's largest rehabilitation centre. As a freestanding facility, GF Strong provides inpatient, outpatient, outreach and clinical support services to clients/patients in four unique programs: Acquired Brain Injury, Spinal Cord Injury, Arthritis and Neuromusculoskeletal. Through its affiliation with the University of British Columbia and other academic organizations, GF Strong participates in leading rehabilitation teaching and research. Dr. George Frederick Strong, a Vancouver internist, became one of the prime movers in the drive to establish a rehabilitation facility in British Columbia, after his daughter sustained a spinal cord injury.
- **The BC Preclinical Research Consortium** (www.bcprc.ca) The BC PRC provides state-of-the-art animal based research tools to investigate models of human disease and to assess safe and effective treatment solutions designed to alter the course of disease development and progression. The goals of the consortium are centered on enabling preclinical research across British Columbia's life sciences sector, creating an unparalleled network of researchers. Development of this internationally competitive network will foster communication, collaboration, education and an overall greater efficiency in animal research in British Columbia, nationally and internationally.

The Next Wave of Medical Device & Diagnostic Innovators

Close behind the commercial members of British Columbia's Medical Device & Diagnostic sector is an impressive group of companies capitalizing on persisting unmet medical needs and the growing understanding of, and capabilities in, personalized medicine. Some of the notable companies in this rapidly advancing group include the following:

- **Aegis Medical** (www.aegismedical.net): Aegis' mission is to develop minimally invasive cardiovascular technology to help prevent strokes in patients with atrial fibrillation. Aegis is working in partnership with Mayo Clinic to develop a simpler, more economical and safer percutaneous procedure for left atrial appendage (LAA) closure that will provide significant advantages to the patient, physician and payers over all existing treatments.
- **Sirius Genomics** (www.siriusgenomics.com): Founded in 2001 by local British Columbia physicians Drs. James Russell and Keith Walley, Sirius is venturing into the realm of personalized medicine to discern which patients benefit from specific drug treatments and which do not, in order to offer safer and more rationalized individualized treatment. By correlating genes to phenotypes, Sirius is developing DNA-based diagnostic and pharmacogenetic tests for critical care. Sirius' current focus is concentrated on the development of tests for sepsis, a systemic blood infection.
- **Augurex Life Sciences** (www.augurex.com): Augurex develops biomarkers which are biological indicators of events and conditions in the body. Augurex's lead biomarker is being developed to help physicians determine the degree of structural damage in the joints of arthritis patients.
- **Heart Force Medical** (www.heartforcemedical.com): Until recently, physicians could not quickly and easily measure the mechanical function of the heart without accessing highly specialized medical imaging systems. Heart Force Medical has changed this paradigm with the introduction of its Digital Ballistocardiograph. Heart Force technology is delivered in an easy to use, sensitive technology for the measurement and timing of events in both the systolic and diastolic phases of the cardiac cycle.






A Fertile Landscape

The Medical Device & Diagnostic sector in British Columbia is fueled by a combination of world-class academic and research institutions as well as experienced leaders in industry.

A foundation of strong academia and research are required to supply the necessary human and intellectual capital to form a premier technology cluster. British Columbia has both these features aggregated at the following globally recognized research and academic institutions:

- The BC Cancer Agency (BCCA) – www.bccancer.bc.ca
- The International Collaboration on Repair Discoveries (ICORD) – www.icord.org
- The British Columbia Institute of Technology (BCIT) – www.bcit.ca
- The Centre for Drug Research and Development (CDRD) – www.cdrd.ca
- Genome British Columbia – www.genomebc.ca
- The Michael Smith Foundation for Health Research (MSFHR) – www.msfhr.org
- Simon Fraser University (SFU) – www.sfu.ca
- The TRI-University Meson Facility (TRIUMF) – www.triumf.ca
- Thompson Rivers University – www.tru.ca
- The University of British Columbia (UBC) – www.ubc.ca
- The University of British Columbia Okanagan – www.ubc.ca/Okanagan
- The University of Northern British Columbia (UNBC) – www.unbc.ca
- The University of Victoria (UVIC) – www.uvic.ca





Additional notable features and recent developments in BC's Medical Device & Diagnostic and overall life science research community include:

- The announcement of a new, state-of-the-art research pavilion to be established at Vancouver General Hospital, housing three internationally-recognized research programs. The seven-storey, 69,350 sq. ft. facility will house three of VGH's key research programs: the **Vancouver Prostate Centre** at VGH; the **Centre for Hip Health and Mobility**; and the **Ovarian Cancer Research Initiative**.
- The opening of the **Blusson Spinal Cord Centre**, representing the world's largest, most advanced and most comprehensive facility devoted to spinal cord injury research and patient care in November 2008. Residing at the Blusson site, ICORD (International Collaboration On Repair Discoveries) is an interdisciplinary research centre for the development of effective strategies to promote functional recovery after spinal cord injury. This unique initiative brings together spinal cord injury researchers from the sciences, medicine, surgery, rehabilitation, engineering, education, and community-based humanities research. ICORD is working to facilitate the discovery and implementation of relevant solutions to improve functional recovery, mobility, community integration and quality of life for people with spinal cord injury. The Blusson building is named after Dr. Stewart and Marilyn Blusson in recognition of their generous donation to the Rick Hansen Foundation in support of this new building, which also houses VCH's Brenda and David McLean Integrated Spine Clinic, and the Rick Hansen Institute.
- A strong legacy left by the University of British Columbia's late Nobel Laureate in Chemistry, **Dr. Michael Smith**. Dr. Smith was a catalyst for the tremendous increase in research in British Columbia that has occurred over the past decade; and no organizations have had a greater impact on this continued increase than Genome British Columbia (www.genomebc.ca) and the Michael Smith Foundation for Health Research (www.msfr.org) – each mandated with supporting research, training, and education and working to position British Columbia as a leader in life science research.

The Blusson Spinal Cord Centre is the world's largest, most advanced and most comprehensive facility devoted to spinal cord research.



Further Fueling Medical Device & Diagnostic Commercialization in BC

In February of 2008, British Columbia's life sciences research community again distinguished itself as true national leaders in applied research by securing the largest amount of Federal Government funding (approx. CAD \$60 million) to create four new Centres of Excellence for Commercialization and Research (CECRs) in BC. The award saw \$163 million invested towards establishing 11 new CECRs across Canada. The most awards granted to any province are in British Columbia, with each of the four having received \$14.95 million.

Recipients of CECR awards include:

- **The Prostate Centre's Translational Research Initiative for Accelerated Discovery and Development (PC-TRIADD)** – PC-TRIADD acts as a bridge between academia and the biotechnology and pharmaceutical industry to conduct pre-clinical and clinical proof-of-concept studies on projects originating in both academia and industry. Its primary focus is on the mechanisms of late stage tumour progression and acquired treatment resistance in prostate cancer. PC-TRIADD is under the direction of leading urologist and surgeon Dr. Martin Gleave, who also holds BC's Leadership Chair in Prostate Cancer Research and is co-founder of BC-based biotech company and recent success story, OncoGenex Technologies.
- **The Prevention of Epidemic Organ Failure (PROOF)** – Led by UBC's Dr. Bruce McManus, PROOF aims to lead the way in finding practical solutions to vital organ failure and reducing organ failure's impact on Canadians and the national healthcare system. PROOF's team of world-class researchers, scientists and clinicians are committed to improving the standard of care and quality of life for all patients in Canada faced with heart, lung and kidney failure.
- **The Centre for Drug Research and Development (CDRD)** – CDRD guides early-stage discoveries made by BC's top academic and health researchers through the preclinical drug development process. CDRD's expertise and facilities help researchers overcome obstacles to the overhead intensive, early development and testing of innovative pharmaceuticals towards bridging the gap between applied research and clinical testing.
- **Advanced Applied Physics Solutions (AAPS)** – Established at TRIUMF, Canada's national laboratory for research into particle and nuclear physics, AAPS' mission is to commercialize advanced physics technologies for the social and economic well-being of Canadians and individuals around the world. Few people recognize that physics innovation at TRIUMF has contributed to the health and biopharmaceutical fields of radio-labeled pharmaceuticals, radio-imaging technologies including positron emission tomography and proton treatment of certain types of ocular cancer.

Most of British Columbia's Medical Device & Diagnostic companies have formed as spin-offs from public research institutions and initiatives such as the above, and have been nurtured by the province's researchers and business leaders with significant, relevant expertise, passion and entrepreneurial spirit.



Leveraging Our Industry Leaders

A significant aspect of device development is engineering, whether it be mechanical, electrical or biomechanical. Entrepreneurs, inventors and senior technical members of the Medical Device & Diagnostic community draw from extensive prior experience with global industry leaders including:

- **Medtronic:** Trevor McCaw, President & Founder of local cardiology device developer Aegis Medical, leveraged his experience with Medtronic to develop Aegis' innovative percutaneous procedure for left atrial appendage (LAA) closure. This technology is intended to effectively treat atrial fibrillation patients and decrease or eliminate their risk of stroke. Medtronic is a multinational, medical device company with a strong presence in British Columbia, and a leading position in the areas of Cardiac Rhythm Disease Management, Spinal and Biologics, Cardiovascular, Neuromodulation, Diabetes, and Surgical Technologies.

Members of the Medical Device & Diagnostic community draw from extensive prior experience with global industry leaders.

- **CREO / Eastman Kodak:** Three of four of Kardium's top executive hail from what was CREO Inc., acquired by Eastman Kodak in June of 2005. While CREO was primarily a digital imaging solutions firm, the engineering expertise that arose from the development of its leading computer-to-plate equipment, workflow software, prepress, proofing, digital plates, scanning and image capture technology has provided the technical know-how to support Kardium's novel development of new technologies for sternal closure following open heart procedures and percutaneous treatments for atrial fibrillation and mitral valve regurgitation.



Compelling Incentives

Complementing BC's wealth in research and discovery, the simultaneous emergence of a business environment readily enabling the translation of research into commercial success has produced great value in BC for global partners and investors.

The Federal and Provincial governments back research-based companies, including Medical Device & Diagnostic companies, through the federal Scientific and Experimental Development Tax Credit Program (SR&ED) that provides Canadian companies with refundable tax credits of 35% of eligible R&D expenditures up to \$2 million per annum plus 20% of other qualified expenditures. Foreign companies qualify for a 20% credit against taxes payable for eligible expenditures, but credits are non-refundable.

BC is the first jurisdiction in North America to grant companies a corporate tax refund based on revenue from life sciences patents.

The BC government provides an additional refundable 10% tax credit against provincial taxes for eligible R&D expenditures for Canadian companies. Foreign companies qualify for the same credit, but it is not refundable.

British Columbia is also the first jurisdiction in North America to grant companies a corporate tax refund based on revenue from life sciences patents. BC's International Financial Activity Act (IFAA) allows incorporated Canadian companies with permanent establishments in BC a refund of income tax paid on international income from commercialization of certain life sciences patents. The maximum refund is the lesser of \$8 million or 75% of corporate income tax payable, allowing commercially successful companies to re-invest in research and development at an accelerated pace.

BC's Small Business Venture Capital Act (SBVCA) provides resident and corporate investors into venture capital funds or eligible small businesses with a tax credit of 30%. Individuals are subject to a maximum refundable credit of \$60,000 per annum; corporate credits are not refundable. Eligible manufacturers also can receive an exemption from provincial sales tax on production equipment and machinery.

A Dedicated Industry Association

In 2007, LifeSciences BC expanded its mandate to support the Medical Device & Diagnostic sector after a merger with the former BC MedTech association. Via this merger, an enhanced industry association that builds upon the strengths of Life Sciences BC and the many accomplishments of BC MedTech was created.

Through LifeSciences BC's dynamic network, we now support and represent the entire life sciences community from Medical Devices & Diagnostics through to biopharmaceuticals, bioproducts and bioenergy, ensuring that no life sciences sector is working in isolation – that all of these sectors work together in a comprehensive, complementary and coordinated fashion.

LifeSciences BC's four strategic areas of focus are:

1. Active facilitation of partnering and investment
2. Advocacy and public policy development
3. Promotion of our world-class science and life sciences industry
4. Attraction, development and retention of human capital



In Summary

With our world-class research, enabling business environment, track record of commercial success, and an unparalleled quality of life, it's easy to see why the global Medical Device & Diagnostic sector is turning its attention to British Columbia.

In short, British Columbia's magic is based on having all the right ingredients for success:

- **World-class applied science**
- **Great academic institutions**
- **A track record of commercial success**
- **Compelling business incentives**
- **Consistent value resulting in a high return on investment**
- **Ability to attract top talent**
- **Quality of work and of life**

The resulting possibilities in British Columbia's life sciences industry are truly vast, and we welcome your involvement in this pioneering initiative.



Contact us

For further information on British Columbia's leading Medical Device & Diagnostic sector and broader life sciences industry, or how LifeSciences British Columbia is supporting this vibrant sector, please contact:

LifeSciences BC

900 – 1188 West Georgia Street
Vancouver, British Columbia
V6E 4A2

Tel: 604 669 9909
Fax: 604 669 9912
Email: info@lifesciencesbc.ca

www.lifesciencesbc.ca

Through LifeSciences BC's dynamic network, we now support and represent the entire sciences community from Medical Devices & Diagnostics through to biopharmaceuticals, bioproducts, and bioenergy.



Defining the Terms

A **Medical Device** is a product which is used for medical purposes in patients, in diagnosis, therapy or surgery. If applied to the body, the effect of the Medical Device is primarily physical, in contrast to pharmaceutical drugs, which exert a biochemical effect. Specific regional definitions of a Medical Device vary slightly as detailed below. Medical Devices include a wide range of products varying in complexity and application. Examples include tongue depressors, medical thermometers, blood sugar meters, and X-ray machines.

In the medical sense, a **Diagnostic** is any tool used in the identification of a medical condition or disease identified by its signs, symptoms, and from the results of various observational procedures. A **Prognostic**, on the other hand, is a tool used to describe the likely outcome of an illness.



About Lifesciences British Columbia

LifeSciences British Columbia supports and represents the biopharmaceutical, medical device, diagnostic, bioproducts, bioenergy and greater life sciences community of British Columbia through leadership, advocacy and promotion of our world-class science and industry. Via active facilitation of partnering and investment into the life sciences sector, British Columbia is fast becoming a global life sciences leader. LifeSciences British Columbia is a not-for-profit, non-government industry association.

www.lifesciencesbc.ca

